Litcius/Paper detail

Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley stage 1 hidradenitis suppurativa: prospective short-term trial and 1-year follow-up in 28 consecutive patients

M. Delage, Jean-Philippe Jaı̈s, Thi Lam, Hélène Guet‐Revillet, Marie‐Noëlle Ungeheuer, Paul‐Henri Consigny, Aude Nassif, Olivier Join‐Lambert

2020Journal of the American Academy of Dermatology34 citationsDOIOpen Access PDF

Topics & Concepts

MedicineMoxifloxacinMetronidazoleSurgeryHidradenitis suppurativaProspective cohort studyInternal medicineClinical endpointAdverse effectGastroenterologyClinical trialAntibioticsDiseaseBiologyMicrobiologyHidradenitis Suppurativa and TreatmentsAcne and Rosacea Treatments and EffectsAnorectal Disease Treatments and Outcomes
Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley stage 1 hidradenitis suppurativa: prospective short-term trial and 1-year follow-up in 28 consecutive patients | Litcius